Understanding COVID-19 Infection in Pregnant Women and Their Babies: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Understanding COVID-19 Infection in Pregnant Women and Their Babies (NCT04703270), a registered phase not stated study. The primary outcome is Antibody Concentrations in Maternal Blood in Pregnant Women in England.

2. Clinical Question

3. Trial Design

The registry describes a national study of pregnant women and their babies, with a stated aim of determining SARS-CoV-2 seroepidemiology among expectant mothers and infants in the U.K. The record lists enrollment of 881 and status as completed. The recorded study start is 2021-01-04, and primary completion is recorded as 2022-04-30. The sponsor is St George's, University of London.

The study is organized around participant infection and antibody categories rather than random assignment. The exposed group is defined by a positive SARS-CoV-2 nasopharyngeal swab at any point during pregnancy from 24 weeks gestation, regardless of antibody status. The seropositive group is defined by a negative swab and positive IgM/IgG antibodies; the unexposed group by a negative swab and negative IgM/IgG antibodies. The record also uses vaccinated and vaccinated-and-exposed labels in its safety information. The registry record does not describe how vaccination status was defined or assigned.

Because allocation is not stated and the groups reflect recorded status, the comparison is observational, not a randomized trial contrast. Differences between categories could reflect factors other than the category itself. The registry record specifically cautions that the arms are not a like-for-like control comparison. A protocol for recruitment, testing schedules beyond the stated primary-outcome timeframe, or adjustment for group differences is not reported in the registry record.

The primary outcome is maternal blood antibody concentration at delivery. Named secondary outcomes concern antibody detection in breast milk, rtPCR results in mother-infant samples, and whether virus can be grown in vitro from specified samples. The record lists 10 outcome measures and 0 analyses. Numerical outcome results are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Participants had their antibodies against SARS-CoV-2 tested prior to assignment of a group.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Antibody Concentrations in Maternal Blood in Pregnant Women in England, measured over Delivery.

The primary endpoint is antibody concentration in maternal blood in pregnant women in England, assessed at delivery. The measure is identified as ADCD-S values, expressed in CAU/ml. The registry specifies a geometric mean as the summary parameter and an inter-quartile range as the dispersion measure, but reports no numerical concentration estimate or group-specific result.

In general, antibody concentration is used to describe the amount of a measurable immune marker in a sample. The geometric mean summarizes values on a multiplicative scale and can be suitable when measurements are skewed rather than symmetrically distributed. The inter-quartile range describes the spread across the central portion of observed values; it does not, by itself, describe uncertainty in an estimated mean. These are general statistical interpretations of the summary measures named in the registry.

The endpoint can describe antibody levels at delivery, but interpretation depends on the assay, the available samples, and the analysis population. Details about assay validation, handling of values below detection limits, sample completeness, and the number of measurements contributing to the endpoint are not reported in the registry record. Without the posted concentration results, the direction, magnitude, and precision of any difference between exposure categories cannot be assessed.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The statistical methods that can be identified from the registry record are limited. It names maternal blood antibody concentration at delivery as the primary outcome, specifies ADCD-S values in CAU/ml, and identifies the geometric mean and inter-quartile range as the summary parameter and dispersion measure. It lists 0 analyses. A statistical analysis plan, model, hypothesis test, or procedure for estimating uncertainty is not reported in the registry record.

What does a geometric mean describe?

In general, a geometric mean summarizes measurements after taking logarithms, averaging on that scale, and transforming back. This approach can be informative when positive measurements vary multiplicatively or have a right-skewed distribution. It differs from an arithmetic mean, which summarizes values on their original additive scale. The geometric mean is not a median and does not show the range of individual measurements. Its usefulness depends on the measurement scale and the distribution of the observed values.

The registry names an inter-quartile range alongside the geometric mean. In general, the inter-quartile range describes the spread between the lower and upper quartiles of observed measurements. It is a descriptive measure of variability among measurements, not a confidence interval for the geometric mean. The actual quartile values and the number of observations used to calculate them are not reported in the registry record.

What would a comparison require?

A comparison of antibody concentrations between categories would need a clearly defined contrast, an analysis population, and a method suited to the outcome distribution. Depending on the data and scientific question, an analysis might compare transformed measurements or use a model that accounts for relevant participant characteristics. This is general statistical context, not a description of methods used in this study. The registry record does not report a planned or completed comparative method, covariate adjustment, or an estimate of a between-group contrast.

The groups are observational status categories. In general, random assignment can support causal comparisons by balancing measured and unmeasured factors in expectation, while observational categories can differ for many reasons. Here, allocation is not stated, and the registry record explicitly says the arms are not a like-for-like control comparison. Thus, even if group-specific estimates were available, an unadjusted difference would describe an association between category and measured antibody concentration, not necessarily an effect caused by infection status.

How should precision be assessed?

In general, an estimate is more informative when accompanied by a measure of uncertainty, such as a confidence interval. A confidence interval communicates the precision of an estimate under the assumptions of the analysis; it does not remove bias from confounding, selective measurement, or missing data. No primary-outcome confidence interval, standard error, or other uncertainty estimate is reported in the registry record. The precision of the maternal antibody outcome therefore cannot be evaluated from the registry information.

The registry record also describes sample-size planning illustrations as based on a fraction of an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. These are planning assumptions, not the trial's own design justification. The illustration outputs and an observed primary-outcome effect are not reported in the registry record. Such planning quantities, when available, would be hypothetical participant requirements under stated assumptions; they would not be observed power or evidence that an effect was detected.

What does over-dispersion mean in general?

Over-dispersion occurs when observed variability is greater than a statistical model expects. For count outcomes, this can make standard errors too small if the model assumes less variability than the data contain. Methods that accommodate over-dispersion can yield more realistic uncertainty. This is general guidance, not a claim that over-dispersion occurred in this study. The registry record does not report the count data or models needed to assess it.

The listed secondary outcomes span different sample types and measurement processes: antibody detection, rtPCR status, and virus growth in vitro. In general, each outcome may need its own definition of the analysis population, handling of unavailable samples, and summary or model. The registry record does not describe those procedures or provide the outcome results. No assumptions about models, adjustments, interim analyses, or the handling of assay limits can be inferred from the endpoint labels alone.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists 10 outcome measures and 0 analyses. The primary outcome is maternal blood antibody concentration at delivery; named secondary outcomes include breast-milk antibody detection, rtPCR findings in maternal and infant samples, and virus growth in vitro in specified samples. The record does not report which outcomes were analyzed, whether any were designated as confirmatory, or how multiple outcomes were handled.

In general, examining multiple outcomes can increase the chance of a nominally unusual result arising by chance. Statistical plans may address this by prioritizing outcomes, adjusting inference, or treating secondary findings as descriptive. The registry record does not report a multiplicity strategy, so no claim about adjustment or control of false-positive findings is possible.

Missing-data methods and analysis populations are also not reported in the registry record. The enrollment figure does not establish how many measurements were available for each outcome, whether samples were missed, or how incomplete records were handled. It is not reported whether the primary analysis included all enrolled participants, participants with a delivery sample, or another defined population. The registry record also does not state whether missingness was assessed or whether any imputation or sensitivity analysis was undertaken.

In general, missingness can affect both the representativeness of an estimate and its precision, particularly if availability of a sample is related to participant characteristics or outcome status. Without counts of available samples and a description of handling, the extent and direction of any such effect cannot be assessed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The safety record lists serious and other adverse-event counts for Exposed, Unexposed, Vaccinated, and Vaccinated and Exposed groups. In each listed group, the reported number at risk for serious adverse events matches the reported number at risk for other adverse events; the affected count is 0 for both categories, and deaths are 0. The at-risk figures are 173 for Exposed, 627 for Unexposed, 43 for Vaccinated, and 38 for Vaccinated and Exposed.

These figures describe what is entered in the registry safety record. They do not show whether every participant was monitored for the same duration, whether all events were collected, or what event definitions and reporting procedures were used; those details are not reported in the registry record. The record lists no serious adverse-event terms. A reported count of 0 should therefore be read as no events recorded in these fields, not as proof that no event could occur or that the groups had equivalent safety.

The groups are not randomized comparison arms according to the registry record, so their safety counts should not be interpreted as a causal comparison. The record does not provide a statistical comparison of adverse events.

12. What the Result Does, and Does Not, Mean

The registry record establishes the study's stated focus: SARS-CoV-2 infection and antibody patterns among pregnant women and their babies. It identifies maternal blood antibody concentration at delivery as the primary outcome and describes group definitions based on swab and antibody status. It also identifies secondary outcome types involving breast milk, maternal and infant samples, placental samples, and in-vitro viral growth.

It does not report numerical results for the primary antibody endpoint or the named secondary outcomes. There are no reported concentration estimates, group contrasts, confidence intervals, or outcome counts in the record. It is therefore not possible to determine the size or precision of any association from the registry information. The completed status and enrollment of 881 do not supply those missing results.

The exposure categories are not randomized, and the registry cautions that the arms are not a like-for-like control comparison. Consequently, the categories can support descriptive characterization, but they do not alone identify a causal effect. The registry record does not report adjustment methods or other analysis details that might address differences between groups.

In general, an antibody measurement is a marker measured in a particular sample and at a particular time. It should not be treated as interchangeable with a clinical outcome or as a direct measure of all aspects of immunity. That distinction is general; the registry's primary endpoint is specifically a maternal blood antibody concentration at delivery. The record does not report findings that would support further conclusions about clinical outcomes, transmission, or protection.

The safety figures record 0 affected participants and 0 deaths in each listed group, but the registry does not describe event ascertainment or monitoring details. These entries should be interpreted as registry counts rather than as comprehensive evidence about risk. Overall, the record describes a study question and outcome framework, while leaving the quantitative results and inferential conclusions unreported.

13. Why This Trial Matters Statistically

This study is statistically relevant because it distinguishes several patterns of SARS-CoV-2 test and antibody status during pregnancy, then identifies antibody concentration in maternal blood at delivery as its primary measure. Those definitions matter: a positive swab, antibody positivity without a positive swab, and negative results for both are not interchangeable classifications. A clear description of the categories helps readers understand what a proposed comparison would represent.

The design also illustrates the difference between a descriptive observational study and a randomized comparison. Categories based on participants' recorded status can be useful for describing the distribution of markers and outcomes. They do not, by themselves, ensure that groups are comparable with respect to other characteristics. The registry record explicitly notes that these are not like-for-like control arms, which is an important qualification for interpretation.

Endpoint specification is also important. The registry identifies the sample, timing, unit, and summaries for the primary outcome. These details clarify what is intended to be measured and how its distribution might be described. At the same time, no concentration results or analysis details are reported, so the registry cannot answer how large or precise any observed differences were.

The secondary outcome definitions span multiple biological samples and types of measurement. In general, such outcomes can add context, but their interpretation depends on consistent collection and analysis and on transparent reporting of available samples. The registry record lists these outcome areas without reporting their numerical results or missing-data procedures. The record therefore has statistical value as a design and measurement description, while its unreported results constrain conclusions about patterns or associations.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation for interpretation is that numerical results are not reported in the registry record. Although the primary endpoint is defined as maternal blood antibody concentration at delivery, the record does not report its estimates, spread, uncertainty, or any comparison between groups. Results for the named secondary outcomes are also not reported.

The registry lists enrollment of 881 but does not report how many participants contributed to each outcome or category. The outcome-specific analysis populations, sample availability, and handling of missing measurements are not reported in the registry record. These omissions prevent assessment of precision and of whether the measured participants represent the enrolled population.

The category definitions depend on test and antibody status during pregnancy from 24 weeks gestation. The registry record does not describe the detailed timing or frequency of testing, assay characteristics, or how uncertain or unavailable test results were handled. It also does not give a detailed definition for the vaccinated groups in the safety record.

Allocation is not stated, and the registry cautions that the groups are not a like-for-like control comparison. The record does not report an adjustment strategy or an analysis plan that could clarify how differences between participants were addressed. The statistical plan, multiplicity approach, and missing-data methods are not reported in the registry record.

Finally, the safety information gives at-risk and affected counts but does not report event definitions, monitoring duration, or ascertainment procedures. These limitations concern what can be concluded from the registry record; they do not establish whether additional methods or results exist outside it.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Understanding COVID-19 Infection in Pregnant Women and Their Babies — NCT04703270.
• Registry record last updated 2025-06-18; status last verified 2024-08.
• Results first posted 2025-06-18.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT04703270, titled Understanding COVID-19 Infection in Pregnant Women and Their Babies, is listed as completed. The sponsor is St George's, University of London. The recorded study start is 2021-01-04, primary completion is 2022-04-30, and enrollment is 881.

The stated aim is to determine SARS-CoV-2 seroepidemiology among expectant mothers and infants in the U.K. The primary outcome is maternal blood antibody concentration in pregnant women in England at delivery, reported as ADCD-S values in CAU/ml with a geometric mean and inter-quartile range specified. The registry record lists 10 outcome measures and 0 analyses.

The record defines exposed, seropositive, and unexposed pregnancy categories, and lists additional vaccination-related groups in the safety information. Numerical primary and secondary outcome results and the statistical analysis details are not reported in the registry record.